Persistence of the carteolol hydrochloride/latanoprost fixed-combination ophthalmic solution, compared with the other β-blocker/prostanoid FP receptor agonist fixed-combination ophthalmic solutions
Purpose To investigate the treatment persistence of carteolol hydrochloride/latanoprost fixed-combination ophthalmic solution (CAR/LAT) and other β-blocker/prostanoid FP receptor agonist fixed-combination ophthalmic solutions (BB/FP) in the treatment of glaucoma. Study design Retrospective observati...
Gespeichert in:
| Veröffentlicht in: | Japanese journal of ophthalmology 2023-11, Vol.67 (6), p.658-667 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 667 |
|---|---|
| container_issue | 6 |
| container_start_page | 658 |
| container_title | Japanese journal of ophthalmology |
| container_volume | 67 |
| creator | Kashiwagi, Kenji Ouchi, Kentaro Shibasaki, Yoshiyuki Suginaka, Masaki |
| description | Purpose
To investigate the treatment persistence of carteolol hydrochloride/latanoprost fixed-combination ophthalmic solution (CAR/LAT) and other β-blocker/prostanoid FP receptor agonist fixed-combination ophthalmic solutions (BB/FP) in the treatment of glaucoma.
Study design
Retrospective observational cohort study.
Methods
A retrospective observational cohort study using JMDC Claims Database. Patients aged 20 years or older diagnosed with glaucoma between February 1, 2017, and March 31, 2020, and prescribed CAR/LAT or another BB/FP were included.
Results
A total of 16,612 patients (7423 in the CAR/LAT group and 9189 in the other BB/FP group) were included. The cumulative treatment persistence rate at the end of follow-up was 42.0% (64.9% at 1 year, 53.4% at 2 years, 45.0% at 3 years, and 42.0% at 4 years) in the CAR/LAT group and 34.7% (54.8% at 1 year, 43.6% at 2 years, 37.1% at 3 years, and 34.7% at 4 years) in the other BB/FP group. Treatment persistence was significantly longer in the CAR/LAT group compared to that in the other BB/FP group (hazard ratio 0.747, p < 0.0001). Over the treatment period, the number of patients who discontinued treatment was 3281 (44.2%) in the CAR/LAT group and 4926 (53.6%) in the other BB/FP group; the median duration of treatment was 135 days and 97 days, respectively.
Conclusion
The study results suggest that persistence rates vary depending on the BB/FP and CAR/LAT appears to be more persistent than other BB/FP. |
| doi_str_mv | 10.1007/s10384-023-01020-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2853941828</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2853941828</sourcerecordid><originalsourceid>FETCH-LOGICAL-c303t-90abf32b683e0fa6d615ec9ab532eea7135f23a7a8ee52bd32f3b065d9a06ac83</originalsourceid><addsrcrecordid>eNqNkcGKFDEQhoMoOK6-gKeAFw_GqSSTnu6jLO4qLLgHPYfqdPV21kynTTK4-1o-xB59JjMzguBBvKQgfPVVUT9jLyW8lQDbdZag240ApQVIUCDaR2wlG6mFUpvmMVsBKCmMNOYpe5bzLQBslFYr9nBNKftcaHbE48jLRNxhKhRDDHy6H1J0U4jJD7QOWHCOS4q58NHf0SBc3PV-xuLjzOMylQnDzjueY9gf_t7wCiyYaODffZmO8lifxH_-EH2I7iul9dFXvX7gF9c8kaOlxMTxJs7-fwfl5-zJiCHTi9_1jH25eP_5_IO4-nT58fzdlXAadBEdYD9q1TetJhixGRppyHXYG62IcCu1GZXGLbZERvWDVqPuoTFDh9Cga_UZe33y1q2_7SkXu_PZUQg4U9xnq1qju41s1QF99Rd6G_dprttVqpPStFutKqVOlKtnyIlGuyS_w3RvJdhDtPYUra3R2mO09qDWp6Zc4fmG0h_1P7p-ARZTrm0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2891158732</pqid></control><display><type>article</type><title>Persistence of the carteolol hydrochloride/latanoprost fixed-combination ophthalmic solution, compared with the other β-blocker/prostanoid FP receptor agonist fixed-combination ophthalmic solutions</title><source>SpringerLink Journals</source><creator>Kashiwagi, Kenji ; Ouchi, Kentaro ; Shibasaki, Yoshiyuki ; Suginaka, Masaki</creator><creatorcontrib>Kashiwagi, Kenji ; Ouchi, Kentaro ; Shibasaki, Yoshiyuki ; Suginaka, Masaki</creatorcontrib><description>Purpose
To investigate the treatment persistence of carteolol hydrochloride/latanoprost fixed-combination ophthalmic solution (CAR/LAT) and other β-blocker/prostanoid FP receptor agonist fixed-combination ophthalmic solutions (BB/FP) in the treatment of glaucoma.
Study design
Retrospective observational cohort study.
Methods
A retrospective observational cohort study using JMDC Claims Database. Patients aged 20 years or older diagnosed with glaucoma between February 1, 2017, and March 31, 2020, and prescribed CAR/LAT or another BB/FP were included.
Results
A total of 16,612 patients (7423 in the CAR/LAT group and 9189 in the other BB/FP group) were included. The cumulative treatment persistence rate at the end of follow-up was 42.0% (64.9% at 1 year, 53.4% at 2 years, 45.0% at 3 years, and 42.0% at 4 years) in the CAR/LAT group and 34.7% (54.8% at 1 year, 43.6% at 2 years, 37.1% at 3 years, and 34.7% at 4 years) in the other BB/FP group. Treatment persistence was significantly longer in the CAR/LAT group compared to that in the other BB/FP group (hazard ratio 0.747, p < 0.0001). Over the treatment period, the number of patients who discontinued treatment was 3281 (44.2%) in the CAR/LAT group and 4926 (53.6%) in the other BB/FP group; the median duration of treatment was 135 days and 97 days, respectively.
Conclusion
The study results suggest that persistence rates vary depending on the BB/FP and CAR/LAT appears to be more persistent than other BB/FP.</description><identifier>ISSN: 0021-5155</identifier><identifier>EISSN: 1613-2246</identifier><identifier>DOI: 10.1007/s10384-023-01020-8</identifier><language>eng</language><publisher>Tokyo: Springer Japan</publisher><subject>Agonists ; Beta blockers ; Clinical Investigation ; Cohort analysis ; Glaucoma ; Medicine ; Medicine & Public Health ; Observational studies ; Ophthalmology ; Receptors</subject><ispartof>Japanese journal of ophthalmology, 2023-11, Vol.67 (6), p.658-667</ispartof><rights>Japanese Ophthalmological Society 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c303t-90abf32b683e0fa6d615ec9ab532eea7135f23a7a8ee52bd32f3b065d9a06ac83</cites><orcidid>0000-0001-8506-8503</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10384-023-01020-8$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10384-023-01020-8$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,41467,42536,51297</link.rule.ids></links><search><creatorcontrib>Kashiwagi, Kenji</creatorcontrib><creatorcontrib>Ouchi, Kentaro</creatorcontrib><creatorcontrib>Shibasaki, Yoshiyuki</creatorcontrib><creatorcontrib>Suginaka, Masaki</creatorcontrib><title>Persistence of the carteolol hydrochloride/latanoprost fixed-combination ophthalmic solution, compared with the other β-blocker/prostanoid FP receptor agonist fixed-combination ophthalmic solutions</title><title>Japanese journal of ophthalmology</title><addtitle>Jpn J Ophthalmol</addtitle><description>Purpose
To investigate the treatment persistence of carteolol hydrochloride/latanoprost fixed-combination ophthalmic solution (CAR/LAT) and other β-blocker/prostanoid FP receptor agonist fixed-combination ophthalmic solutions (BB/FP) in the treatment of glaucoma.
Study design
Retrospective observational cohort study.
Methods
A retrospective observational cohort study using JMDC Claims Database. Patients aged 20 years or older diagnosed with glaucoma between February 1, 2017, and March 31, 2020, and prescribed CAR/LAT or another BB/FP were included.
Results
A total of 16,612 patients (7423 in the CAR/LAT group and 9189 in the other BB/FP group) were included. The cumulative treatment persistence rate at the end of follow-up was 42.0% (64.9% at 1 year, 53.4% at 2 years, 45.0% at 3 years, and 42.0% at 4 years) in the CAR/LAT group and 34.7% (54.8% at 1 year, 43.6% at 2 years, 37.1% at 3 years, and 34.7% at 4 years) in the other BB/FP group. Treatment persistence was significantly longer in the CAR/LAT group compared to that in the other BB/FP group (hazard ratio 0.747, p < 0.0001). Over the treatment period, the number of patients who discontinued treatment was 3281 (44.2%) in the CAR/LAT group and 4926 (53.6%) in the other BB/FP group; the median duration of treatment was 135 days and 97 days, respectively.
Conclusion
The study results suggest that persistence rates vary depending on the BB/FP and CAR/LAT appears to be more persistent than other BB/FP.</description><subject>Agonists</subject><subject>Beta blockers</subject><subject>Clinical Investigation</subject><subject>Cohort analysis</subject><subject>Glaucoma</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Observational studies</subject><subject>Ophthalmology</subject><subject>Receptors</subject><issn>0021-5155</issn><issn>1613-2246</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNqNkcGKFDEQhoMoOK6-gKeAFw_GqSSTnu6jLO4qLLgHPYfqdPV21kynTTK4-1o-xB59JjMzguBBvKQgfPVVUT9jLyW8lQDbdZag240ApQVIUCDaR2wlG6mFUpvmMVsBKCmMNOYpe5bzLQBslFYr9nBNKftcaHbE48jLRNxhKhRDDHy6H1J0U4jJD7QOWHCOS4q58NHf0SBc3PV-xuLjzOMylQnDzjueY9gf_t7wCiyYaODffZmO8lifxH_-EH2I7iul9dFXvX7gF9c8kaOlxMTxJs7-fwfl5-zJiCHTi9_1jH25eP_5_IO4-nT58fzdlXAadBEdYD9q1TetJhixGRppyHXYG62IcCu1GZXGLbZERvWDVqPuoTFDh9Cga_UZe33y1q2_7SkXu_PZUQg4U9xnq1qju41s1QF99Rd6G_dprttVqpPStFutKqVOlKtnyIlGuyS_w3RvJdhDtPYUra3R2mO09qDWp6Zc4fmG0h_1P7p-ARZTrm0</recordid><startdate>20231101</startdate><enddate>20231101</enddate><creator>Kashiwagi, Kenji</creator><creator>Ouchi, Kentaro</creator><creator>Shibasaki, Yoshiyuki</creator><creator>Suginaka, Masaki</creator><general>Springer Japan</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-8506-8503</orcidid></search><sort><creationdate>20231101</creationdate><title>Persistence of the carteolol hydrochloride/latanoprost fixed-combination ophthalmic solution, compared with the other β-blocker/prostanoid FP receptor agonist fixed-combination ophthalmic solutions</title><author>Kashiwagi, Kenji ; Ouchi, Kentaro ; Shibasaki, Yoshiyuki ; Suginaka, Masaki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c303t-90abf32b683e0fa6d615ec9ab532eea7135f23a7a8ee52bd32f3b065d9a06ac83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Agonists</topic><topic>Beta blockers</topic><topic>Clinical Investigation</topic><topic>Cohort analysis</topic><topic>Glaucoma</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Observational studies</topic><topic>Ophthalmology</topic><topic>Receptors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kashiwagi, Kenji</creatorcontrib><creatorcontrib>Ouchi, Kentaro</creatorcontrib><creatorcontrib>Shibasaki, Yoshiyuki</creatorcontrib><creatorcontrib>Suginaka, Masaki</creatorcontrib><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Japanese journal of ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kashiwagi, Kenji</au><au>Ouchi, Kentaro</au><au>Shibasaki, Yoshiyuki</au><au>Suginaka, Masaki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Persistence of the carteolol hydrochloride/latanoprost fixed-combination ophthalmic solution, compared with the other β-blocker/prostanoid FP receptor agonist fixed-combination ophthalmic solutions</atitle><jtitle>Japanese journal of ophthalmology</jtitle><stitle>Jpn J Ophthalmol</stitle><date>2023-11-01</date><risdate>2023</risdate><volume>67</volume><issue>6</issue><spage>658</spage><epage>667</epage><pages>658-667</pages><issn>0021-5155</issn><eissn>1613-2246</eissn><abstract>Purpose
To investigate the treatment persistence of carteolol hydrochloride/latanoprost fixed-combination ophthalmic solution (CAR/LAT) and other β-blocker/prostanoid FP receptor agonist fixed-combination ophthalmic solutions (BB/FP) in the treatment of glaucoma.
Study design
Retrospective observational cohort study.
Methods
A retrospective observational cohort study using JMDC Claims Database. Patients aged 20 years or older diagnosed with glaucoma between February 1, 2017, and March 31, 2020, and prescribed CAR/LAT or another BB/FP were included.
Results
A total of 16,612 patients (7423 in the CAR/LAT group and 9189 in the other BB/FP group) were included. The cumulative treatment persistence rate at the end of follow-up was 42.0% (64.9% at 1 year, 53.4% at 2 years, 45.0% at 3 years, and 42.0% at 4 years) in the CAR/LAT group and 34.7% (54.8% at 1 year, 43.6% at 2 years, 37.1% at 3 years, and 34.7% at 4 years) in the other BB/FP group. Treatment persistence was significantly longer in the CAR/LAT group compared to that in the other BB/FP group (hazard ratio 0.747, p < 0.0001). Over the treatment period, the number of patients who discontinued treatment was 3281 (44.2%) in the CAR/LAT group and 4926 (53.6%) in the other BB/FP group; the median duration of treatment was 135 days and 97 days, respectively.
Conclusion
The study results suggest that persistence rates vary depending on the BB/FP and CAR/LAT appears to be more persistent than other BB/FP.</abstract><cop>Tokyo</cop><pub>Springer Japan</pub><doi>10.1007/s10384-023-01020-8</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0001-8506-8503</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0021-5155 |
| ispartof | Japanese journal of ophthalmology, 2023-11, Vol.67 (6), p.658-667 |
| issn | 0021-5155 1613-2246 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2853941828 |
| source | SpringerLink Journals |
| subjects | Agonists Beta blockers Clinical Investigation Cohort analysis Glaucoma Medicine Medicine & Public Health Observational studies Ophthalmology Receptors |
| title | Persistence of the carteolol hydrochloride/latanoprost fixed-combination ophthalmic solution, compared with the other β-blocker/prostanoid FP receptor agonist fixed-combination ophthalmic solutions |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T13%3A52%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Persistence%20of%20the%20carteolol%20hydrochloride/latanoprost%20fixed-combination%20ophthalmic%20solution,%20compared%20with%20the%20other%20%CE%B2-blocker/prostanoid%20FP%20receptor%20agonist%20fixed-combination%20ophthalmic%20solutions&rft.jtitle=Japanese%20journal%20of%20ophthalmology&rft.au=Kashiwagi,%20Kenji&rft.date=2023-11-01&rft.volume=67&rft.issue=6&rft.spage=658&rft.epage=667&rft.pages=658-667&rft.issn=0021-5155&rft.eissn=1613-2246&rft_id=info:doi/10.1007/s10384-023-01020-8&rft_dat=%3Cproquest_cross%3E2853941828%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2891158732&rft_id=info:pmid/&rfr_iscdi=true |